Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Acknowledgements This work was supported
2023-01-21

Acknowledgements This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS) FINEP research grant “Rede Instituto Brasil
-
6063 receptor LPA binds to six specific cell surface GPCR re
2023-01-19

LPA binds to six specific cell surface GPCR receptors. The receptors LPA1 (lysophosphatidic receptor 1, formerly, Edg2), LPA2 (Edg4) and LPA3 (Edg7) belong to the endothelial differentiation gene family (EDG) and share sequence homology (50–60% amino 6063 receptor homology) An et al., 1997, An et al
-
CHK has been reported to be the
2023-01-18

CHK1 has been reported to be the kinase responsible for H3.3S31 phosphorylation in human ALT cancer TG101209 australia . However, in our study, knockdown of CHK1 in HEK293F (Figs. S1c and S6) or HeLa S3 (data not shown) cells did not result in a significant decrease in H3.3S31ph, which is in agreem
-
CHK has been reported to be the
2023-01-18

CHK1 has been reported to be the kinase responsible for H3.3S31 phosphorylation in human ALT cancer TG101209 australia . However, in our study, knockdown of CHK1 in HEK293F (Figs. S1c and S6) or HeLa S3 (data not shown) cells did not result in a significant decrease in H3.3S31ph, which is in agreem
-
Since ARBs strongly reduce inflammation it was
2023-01-16

Since ARBs strongly reduce inflammation, it was hypothesized that the protective effects on cognition were the result of reduction of inflammation and amelioration of neurogenic decrease. However, ARB treatment did not normalize increased inflammation and neurogenic loss. For this reason, the protec
-
Finally intracrine androgen synthesis metabolism can be acti
2023-01-16

Finally, intracrine androgen synthesis/metabolism can be activated thus allowing daprodustat to bypass the low levels of androgens in the circulation by producing androgens themselves (Cai and Balk, 2011, Rahman et al., 2004). Moreover, changes in AR co-regulators like the overexpression of steroid
-
Dose Response Studies Against Puromycin
2023-01-16

Dose–Response Studies Against Puromycin–Sensitive Aminopeptidase (PSA). PSA is a ubiquitous metallopeptidase encoded by the NPEPPS gene with subcellular distribution in the cytosol and nucleus [49]. Comprising of a 919 amino caudatin sequence, it has a broad substrate specificity, and is responsibl
-
This suggestion was confirmed by immunohistochemical studies
2023-01-16

This suggestion was confirmed by immunohistochemical studies in which the immunoreactivity of the enzyme was actually higher at the earlier rather than at the advanced stages of the disease. Importantly, a later study showed that the biochemical signature of 12/15LO enzymatic activation (i.e., 12-HE
-
Inflammatory factors released by activated cells during
2023-01-16

Inflammatory factors released by activated cells during AD are very important for the disease progression. Not only several inflammatory cytokines, such as IL-1β, IL-18, and IL-33, but also anti-inflammatory ones, as IL-10 and IL-13, are upregulated in the brain of AD patients (Morimoto et al., 2011
-
Systematic administration of ABT amino bromophenyl morpholin
2023-01-16

Systematic administration of ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl) pyrido[2,3-d] pyrimidine), a potent and selective non-nucleoside AK inhibitor, also generates analgesic effects in animal models of pain (Jarvis et al., 2000, Kowaluk et al., 2000, Suzuki et al., 2001), sug
-
br Results br Discussion Members of the PfkB family
2023-01-16

Results Discussion Members of the PfkB family of proteins, which exhibit AK activity, have only been found in the eukaryotic organisms in the past. Hence, the report of a PfkB family protein in MTub that exhibited AK activity was of much interest, and it necessitated closer examination of its
-
Until now five muscarinic receptor M genes
2023-01-16

Until now, five muscarinic receptor (M1-5) genes have been cloned, but, M1-3 receptors are functionally recognized in the lungs. Smooth muscle contraction is mainly mediated by M3. M2 may also participate in the contraction via Gi protein which leads to a decrease in cAMP. On the other hand, M2 is l
-
Introduction The lysosomal storage disorder
2023-01-16

Introduction The lysosomal storage disorder Gaucher disease (Mendelian Inheritance in Man, OMIM #230800) results from the recessively inherited deficiency of lysosomal glucocerebrosidase (GCase, EC 3.2.1.45), caused by mutations in the gene GBA1 (MIM# 606463) located on chromosome 1q21. The enzymat
-
paroxetine hydrochloride It has been reported that
2023-01-16

It has been reported that leukotrienes and their receptors, e.g. the cysteinyl leukotriene receptor 1 (CysLT1) may promote paroxetine hydrochloride injury (Ding et al., 2007) and that increased 5-LOX expression and activity lead to production of brain-toxic molecules (Khan et al., 2010). However, d
-
Moreover showed reduction in fibroblast
2023-01-16

Moreover, showed 73% reduction in fibroblast growth factor–induced neovascularization in a mouse corneal micropocket assay at a dose of 100mg/kg and 50% reduction at 50mg/kg. Both results were highly statistically significant (Pintegrin inhibitor have recently shown only moderate efficacy (40% inh
15716 records 344/1048 page Previous Next First page 上5页 341342343344345 下5页 Last page